Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FL115 in Advanced Solid Tumours
NCT07785193Phase 1Not yet recruiting
- Sponsor
- Forlong Biotechnology
- Start
- Sep 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of FL-115 in solid tumor, sponsored by Forlong Biotechnology. Primary endpoints: Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events and Maximum Tolerated Dose and Recommended Phase 2 Dose at 15 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
FL-115
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07785193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07785193.